Who
Menelas N. Pangalos
Director
Company insider
Files Form 4 as: Director, Biogen; Director, Absci.
In numbers
- Trades disclosed
- 26
- Buys
- 3
- Sells
- 0
- Bought
- $1.1M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Jan 2024
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —2,370 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,370 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,370 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —2,370 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,505 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —39,800 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —39,800 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 13 May 2026filed 13 May 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $201K37,453 at $5.36 | filing |
| 13 May 2026filed 13 May 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $201K37,453 at $5.36 | filing |
| 2 Mar 2026filed 5 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —5,800 at $0.00 | filing |
| 2 Mar 2026filed 5 Mar 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —22,800 at $0.00 | filing |
| 2 Mar 2026filed 5 Mar 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —22,800 at $0.00 | filing |
| 2 Mar 2026filed 5 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —5,800 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $206K75,095 at $2.74 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $206K75,095 at $2.74 | filing |
| 22 Sep 2025filed 24 Sep 2025 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $255K95,785 at $2.66 | filing |
| 17 Jun 2025filed 18 Jun 2025 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,370 at $0.00 | filing |
News
Absci (NASDAQ:ABSI) Given New $20.00 Price Target at KeyCorpABSI · themarketsdaily.com · 16 Oct 2026Absci (NASDAQ:ABSI) Price Target Raised to $15.00ABSI · dailypolitical.com · 15 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonABSI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Menelas N. Pangalos; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.